Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT and Nivolumab in Refractory Solid Tumors
NCT04521075Phase 2Unknown
- Sponsor
- Ella Therapeutics
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic fecal microbiota in melanoma, non-small cell lung cancer (NSCLC), solid tumor, sponsored by Ella Therapeutics. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
melanomanon-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04521075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521075.